MAPT and Alzheimer disease: We found significantly increased sleep rebound behavior (P < 0.05) during the dark phase (1800–2100 and 0000–0300 hours, respectively) in AD-tau–injected APPPS1:E4 but not in APPPS1:E3 mice under SD conditions using the PiezoSleep recording system.